Introduction: Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of malignancies arising from the clonal proliferation of B-cell or T-cell lineages, representing the most common hematological malignancy worldwide. Previous studies have shown a rising incidence of this disease over recent years, with increasing prevalence particularly from the sixth decade of life onward. Therefore, epidemiological surveillance, including the description of mortality rates, is essential for the development of strategies for early detection and treatment. Objectives: This study aims to describe the epidemiological profile of deaths due to Non-Hodgkin's lymphoma in Brazil over the past ten years. Methods: This is a retrospective, cross-sectional, and quantitative study. Data collection was performed using the Hospital Information System of the Brazilian Unified Health System (SIH/SUS), stratified by region, from 2015 to 2024. The selected variables for the epidemiological profile included age group, gender, and race/skin color, analyzed based on the number of deaths and mortality rate. Results: During the analyzed period, 14,127 deaths from NHL were recorded, corresponding to an average mortality rate of 8.33%. Regionally, the Southeast accounted for the highest proportion of deaths (44.7%) but had the second-lowest mortality rate (7.95%), while the Central-West region registered the lowest mortality rate in the country (7.87%). In contrast, the North region presented the highest mortality rate (9.12%), despite having the lowest absolute number of deaths (625; 4.4%). The other regions reported the following number and proportion of deaths: Central-West (895 deaths; 6.33%), South (3,064; 21.7%), and Northeast (3,225; 22.8%). Regarding age distribution, the highest frequency of deaths occurred in the 60–69 age group (3,348; 23.7%), with a progressive increase in mortality observed with advancing age, reaching 23.8% in the 80–89 age group. A higher number of deaths was observed among males (8,110; 57.4%). In terms of race/skin color, the highest absolute numbers occurred among White (6,643; 47%) and mixed-race individuals (5,143; 36.4%), while the highest mortality rates were observed in Black (9.0%) and Indigenous (8.9%) populations.Conclusion: The data reveal significant sociodemographic disparities in NHL-related mortality during the analyzed period. Regional differences, particularly the elevated mortality rate in the Northern region, suggest structural deficiencies in access to specialized oncology services, potentially exacerbated by geographic and economic barriers that act as social determinants of health. The higher mortality observed among Black and Indigenous populations underscores persistent inequities in access to modern therapies and appropriate follow-up care. Therefore, the results point to the urgent need to revise the country's oncology care models, considering sociodemographic differences and directing resources to populations most affected by this condition.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
